Terms ending in 2038
Every in-force patent on Genentech, Inc.'s record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,007,267 | ANTI-CD3 Antibodies and Methods of Use In force · Medium confidence | Genentech, Inc. | In force | Medium confidence | |
| US 11,654,105 | Subcutaneous HER2 Antibody Formulations In force · Medium confidence | Genentech, Inc. | In force | Medium confidence | |
| US 11,300,570 | Therapeutic and Diagnostic Methods for Cancer In force · Medium confidence | Foundation Medicine, Inc. | In force | Medium confidence | |
| US 11,702,428 | Chemical Compounds as Inhibitors of INTERLEUKIN-1 Activity In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 11,377,505 | Methods and Formulations for Reducing Reconstitution Time of Lyophilized Polypeptides In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 11,116,840 | Multispecific Antigen-Binding Proteins In force · Medium confidence | Genentech, Inc. | In force | Medium confidence | |
| US 11,925,624 | Methods of Administering Anti-Fibrotic Therapy In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 12,121,586 | Optimized Variants of Anti-VEGF Antibodies In force · Medium confidence | Genentech, Inc. | In force | Medium confidence | |
| US 11,279,767 | Therapeutic and Diagnostic Methods for Cancer In force · High confidence | Foundation Medicine, Inc. | In force | High confidence | |
| US 12,331,128 | Therapeutic and Diagnostic Methods for Cancer In force · High confidence | Foundation Medicine, Inc. | In force | High confidence | |
| 57 more term ends in 2038 · Pro | |||||
10 of 67 patents shown. Soonest term end first, then patent number.
Pro members see all 67.
61 of these are in force and held by Genentech, Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.